CSPC acquires Zhuhai Zhifan, increasing the number of biopharmaceuticals

Recently, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center (Limited Partnership) from an independent third party
.
It is reported that Zhuhai Zhifan’s main business is to invest in Mingkang Biology, and currently holds the registered capital of Guangzhou Mingkang Biological Engineering Co.
, Ltd.
of RMB 94,452,874 (of which RMB 32,866,514 has not yet been paid), accounting for the registration of Mingkang Biology on the date of this announcement.
The total capital is about 51%
.
According to public information, Mingkang Bio is a biotechnology company engaged in the research and development, production and sales of biological drugs
.
He has rich experience in the research and development, production and quality management of new biological drugs, especially in animal cell culture and protein separation technology
.
Among them, it is worth mentioning that the company's self-developed Mingfule (recombinant human TNK tissue plasminogen activator for injection) is a third-generation specific thrombolytic drug with intellectual property rights.
Listed in China for thrombolysis in patients with acute myocardial infarction within 6 hours after onset
.
It is reported that the current unit price of the drug is 4000-8000 yuan/box (1.
0*10E7IU/16mg)
.
The CSPC acquisition of Mingkang Bio will also obtain a new generation of thrombolytic new drug recombinant human TNK tissue plasminogen activator (trade name: Mingfule)
.
In this regard, the relevant person in charge of CSPC clearly stated that the product has good commercial potential, and the acquisition will further strengthen the group's product pipeline and provide new growth drivers
.
The industry believes that for traditional pharmaceutical companies, the acquisition of new companies has already become one of the ways to quickly replenish pipelines
.
In recent years, CSPC has accelerated its efforts to expand and optimize its own pipeline through independent research and development, acquisitions, and new companies, in order to follow the development of the industry..
It is reported that in order to develop innovative drugs last year, CSPC reached several deals with Connoya, respectively obtaining anti-IL-4Rα monoclonal antibody CM310 and anti-TSLP for the treatment of moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
Exclusive rights to recombinant humanized monoclonal antibody CM326 in China (excluding Hong Kong, Macau and Taiwan)
.
At present, through years of innovation and development, CSPC has become an innovative enterprise integrating R&D, production and sales of innovative drugs
.
According to the third quarterly report of 2021 disclosed by CSPC, in the first three quarters of last year, CSPC's revenue was 20.
64 billion yuan, a year-on-year increase of 7.
4%; net profit reached 4.
335 billion yuan, an increase of 23.
2%
.
From the perspective of the reasons for the growth of the performance in the first three quarters, innovative drugs actually contributed
.
In the first three quarters, anti-tumor drugs contributed 5.
778 billion yuan in revenue, becoming a major source of revenue
.
In the future, as CSPC continues to increase its investment in innovative drugs, the industry expects that the company's innovative achievements will continue to emerge, and the innovative drug product pipeline is expected to be more abundant
.